Clinical Trial Update: Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating durvalumab and olaparib in metastatic or recurrent endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Neoplasms
• Endometrium Cancer
• Uterine Neoplasms

Drugs mentioned

• Durvalumab (durvalumab)
• Olaparib (Olaparib)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Endometrial Neoplasms, Uterine Neoplasms | Phase 2 | Status: UNKNOWN